 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | warfarin / Generic mfg.
Journal: Management of Thrombosis in a Patient with Three Thrombophilic Disorders. (Pubmed Central) - Jul 29, 2024
Antithrombin replacement to achieve levels between 80% and 120% with heparin administration was used during the endovascular procedure. The patient is currently asymptomatic and maintains indefinite anticoagulation with warfarin, keeping an appropriate anticoagulation range (international normalized range between 2.5 and 3.5).
- | Journal, Surgery: Antithrombin Replacement in Cardiac Surgery: Was Too Much of a Good Thing Bad? (Pubmed Central) - May 23, 2023
The patient is currently asymptomatic and maintains indefinite anticoagulation with warfarin, keeping an appropriate anticoagulation range (international normalized range between 2.5 and 3.5). No abstract available
- Atenativ (human antithrombin III) / Octapharma
Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency During Surgery or Childbirth (Room:Exhibition) - May 18, 2023 - Abstract #ISTH2023ISTH_945;
P3
To date, two patients have been enrolled, in the US. Study completion is expected in Q3 2024.Conclusion(s): The results from this pivotal registration study are expected to strengthen the available evidence indicating that human plasma-derived antithrombin concentrate effectively prevents thrombotic and thromboembolic events in patients with congenital antithrombin deficiency in surgery and delivery settings and has a favorable safety profile.
- | bivalirudin / Generic mfg.
Journal: Analysis of Wholesale Drug Acquisition and Laboratory Assessment Costs Between Heparin Compared With Bivalirudin-Based Systemic Anticoagulation Strategies in Adult Extracorporeal Membrane Oxygenation. (Pubmed Central) - Apr 17, 2023
Antithrombin assays and supplementation compromise a significant proportion of heparin-based anticoagulation costs in ECMO patients and is substantially reduced when a bivalirudin-based anticoagulation strategy is deployed. A favorable association exists between the aggregate cost of administration of bivalirudin compared with heparin-based systemic anticoagulation in adults supported on ECMO driven by reductions in antithrombin activity assessments and the cost of antithrombin replacement.
- | Journal: Thrombosis questions from the inpatient wards. (Pubmed Central) - Dec 10, 2022
Last, we dissect the major clinical trials of therapeutic- and intermediate-dose anticoagulation and antiplatelet therapy in hospitalized patients with COVID-19, reviewing key recommendations from consensus guidelines while highlighting ways in which institutional and patient-tailored practices regarding antithrombotic therapies in COVID-19 may differ. Together, the cases highlight the diverse and dramatic presentations of macro- and microvascular thrombosis as encountered on the inpatient wards.
- Atenativ (human antithrombin III) / Octapharma
Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173) (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_5630;
P3
Together, the cases highlight the diverse and dramatic presentations of macro- and microvascular thrombosis as encountered on the inpatient wards. This study will endeavor to determine and decrease the incidence of thrombotic and thromboembolic events in subjects with congenital antithrombin deficiency during high-risk periods.
- | Journal: Antithrombin Replacement and Extracorporeal Membrane Oxygenation: The time is ripe for a Simpler Solution. (Pubmed Central) - Oct 7, 2022
This study will endeavor to determine and decrease the incidence of thrombotic and thromboembolic events in subjects with congenital antithrombin deficiency during high-risk periods. No abstract available
- | Journal: A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management. (Pubmed Central) - Sep 29, 2022
Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.
- enoxaparin sodium / Generic mfg.
Management of Antithrombin Deficiency in Pregnancy - 2 cases report (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_2049;
She needed higher doses enoxaparin and ATRT(graph 1), with no bleeding episodes.Case 221 week pregnant woman diagnosed with a DVT and PE, was admitted at her local hospital and started on therapeutic dose enoxaparin 80 mg/bid. 3 days after she entered the ER with a new DVT episode.
- Atenativ (human antithrombin III) / Octapharma
Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency During Surgery or Childbirth (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1482;
P3
Enrollment is estimated to start in Q1 2022 and end in Q3 2024. Conclusion(s): The results from this pivotal registration study are expected to confirm and strengthen available evidence indicating that human plasma-derived antithrombin concentrate is effective in preventing TEs and TEEs in patients with CAD in surgery and delivery, with a favorable safety profile.
- Atenativ (human antithrombin III) / Octapharma
Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4909;
P3
This study will aim to evaluate the efficacy, safety, and pharmacokinetics (PK) of a high-purity, double virus inactivated, lyophilized human antithrombin III concentrate (Atenativ ® ) in these settings... The results from this pivotal registration study are expected to confirm and strengthen the available evidence indicating that human plasma-derived antithrombin concentrate is effective in preventing thrombotic and thromboembolic events in patients with CAD in surgery and delivery settings and has a favorable safety profile.
- ||| Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Clinical, P3 data, Journal: A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol. (Pubmed Central) - Sep 26, 2021
As we have selected a specifically defined target population based on reanalysis of data of a previous plasma-derived antithrombin phase 3 study, the results of our study are expected to provide efficacy and safety data concerning rhAT-gamma treatment in Japanese patients. This study could help identify an effective novel treatment for such patients with early-onset severe preeclampsia for whom appropriate treatment is unavailable.
- [VIRTUAL] MANAGEMENT OF ASPARAGINASE-ASSOCIATED COAGULOPATHY AMONG PEDIATRIC ONCOLOGY PROVIDERS () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_359;
There is a large variation in PHO provider practices for monitoring and management of asparaginase-associated hemostatic derangements. This observation highlights the need for evidence-based guidelines to standardize practices.
- enoxaparin sodium / Generic mfg.
[VIRTUAL] Thromboembolism in adult patients with acute lymphoblastic leukaemia / lymphoma: past and future practice in a tertiary centre () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_51;
Treatment of significant VTE is with therapeutic enoxaparin (minimum of 3 months), dose adjusted for thrombocytopenia (as per BSH guidance) and peak anti‐Xa and antithrombin activity monitoring 3 times per week for 3 weeks after each asparaginase dose. Antithrombin replacement is administered if recent VTE, low antithrombin and/or low anti‐Xa activity.
- enoxaparin sodium / Generic mfg.
Thromboembolism in adult patients with acute lymphoblastic leukaemia / lymphoma: past and future practice in a tertiary centre () - May 14, 2020 - Abstract #BSH2020BSH_376;
Treatment of significant VTE is with therapeutic enoxaparin (minimum of 3 months), dose adjusted for thrombocytopenia (as per BSH guidance) and peak anti‐Xa and antithrombin activity monitoring 3 times per week for 3 weeks after each asparaginase dose. Antithrombin replacement is administered if recent VTE, low antithrombin and/or low anti‐Xa activity.
- || Clinical, Journal: Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. (Pubmed Central) - Apr 16, 2020
Supportive care for DIC and/or asparaginase-induced hemostatic alterations at Japanese pediatric centers was intensive and differs markedly from protocols in other countries. The efficacy of supportive care should be evaluated prospectively in the setting of pediatric leukemia.
- | Retrospective data, Journal: Antithrombin During Extracorporeal Membrane Oxygenation in Adults: National Survey and Retrospective Analysis. (Pubmed Central) - Mar 11, 2020
Antithrombin is frequently supplemented during veno-venous ECMO although low antithrombin activity does not constantly impede, and antithrombin replacement does not constantly ensure, reaching the target aPTT ratio. Inflammation possibly affects the individual response to heparin.
- | Avastin (bevacizumab) / Roche
Review, Journal: Thrombotic Risk from Chemotherapy and Other Cancer Therapies. (Pubmed Central) - Sep 10, 2019
Supportive care agents in cancer care, such as erythropoiesis-stimulating agents, granulocyte colony stimulating factor, and steroids, also have some impact on thrombosis. This review summarizes the mechanisms by which these and other therapies modulate thrombotic risks and how such risks may be managed.